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Introduction
Multiple myeloma (MM), the progressive malignancy of clonal plasma cells is the 2 nd most common hematologic neoplasia 1 and accounts for 1.4 % of all cancers and for 1.8 % of all cancer mortality worldwide. 2 Despite encouraging improvements in the survival of MM myeloma patients over the last decade, the disease remains incurable, even by combination therapies with effective novel pharmacological agents. [2] [3] [4] [5] A novel appealing alternative to these treatments is the targeting of MM with therapeutic antibodies, as already standard-ofcare in several other hematological malignancies. Therefore, we generated the CD38-specific human monoclonal antibody, daratumumab (DARA), which induces MM cell death via various mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). 6 Based on these preclinical data, DARA is currently being evaluated in patients with relapsed/refractory MM, with encouraging results. 7 In previous studies, we demonstrated that DARA-mediated ADCC can be significantly improved by lenalidomide (LEN), mainly due to the potent capacity of LEN to activate NK cells. 8, 9 Based on these observations, we hypothesized that the efficacy of DARA-induced, NK cell-mediated ADCC may be further enhanced via modulation of NK cell regulatory signals transmitted via the inhibitory and activating NK receptors (KIRs; killer-cell immunoglobulin-like receptors). 10, 11 Since the signals transmitted by inhibitory KIRs may prevent NK cell-mediated ADCC, even in the presence of an activating receptor-ligand interaction, 12 we set out to test the possibility to improve DARA efficacy by blocking inhibitory KIRs.
IPH2102 (formerly 1-7F9 and IPH2101) is a hinge-stabilized, human IgG4 monoclonal antibody that blocks the interaction of the three main inhibitory KIR receptors (KIR2DL-1, -2, -3) with their ligands, the human leukocyte antigen-C (HLA-C) molecules. 
MM Cell lines
The CD38 positive, luciferase (LUC)-transduced MM cell lines UM9 and RPMI8226 were cultured in RPMI 1640 (Invitrogen Life Technologies, Carlsbad, California, USA), supplemented with 10% fetal bovine serum (FBS; Integro BV, Salisbury, North Carolina, USA) and antibiotics (100 units/mL penicillin, 100 μ g/mL streptomycin; both Invitrogen Life Technologies) as previously described.
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Peripheral blood mononuclear cells (PBMC) from healthy donors
All procedures involving material from healthy donors were approved by the local institutional medical ethical committee. Peripheral blood from healthy volunteers was obtained after written informed consent. PBMC were isolated by Ficoll-Hypaque densitygradient centrifugation to use as effector cells in ADCC assays.
Immunophenotyping by flow cytometry
Cell surface expression of various receptors was determined by FACS analysis using fluorochrome-conjugated monoclonal antibodies (mAb). PE-conjugated IPH2102 was produced by Innate Pharma. All other mAbs used for phenotyping were purchased from BD Biosciences (Franklin Lakes, New Jersey, USA). Flow cytometry was performed using a FACS-Calibur device (BD Biosciences, Franklin Lakes, New Jersey, USA); data were analyzed using CellQuest software.
Test antibodies
The anti-KIR mAb IPH2102 (formerly 1-7F9/IPH2101) is a hinge-stabilized human IgG4
antibody, anti-KIR2DL1/L2/L3/S1/S2, produced in a CHO cell line and was generated by 
Fc gamma receptor polymorphism genotyping
After isolating the patients' genomic DNA from PBMC, the typing for FcγRIIIa (CD16) polymorphisms (158V/F) on immune effector cells, including NK cells and macrophages, and FcγRIIa (CD32) polymorphisms (131H/R) on immune effector cells, including monocytes, was performed as described by Koene et al. 18 and Jiang et al., 19 respectively.
Statistics
Differences between indicated groups were analyzed for significance in two-tailed paired 
Results
IPH2102 increases DARA-mediated ADCC of MM cells
We first investigated the potential of combining DARA with IPH2102 in standard four-hour ADCC assays using MM cell lines UM9 and RPMI8226 as target cells and PBMC from different healthy donors (n=4) as effector cells. An irrelevant polyclonal IgG4 antibody and an irrelevant IgG1 antibody (IgG1-b12) were used as isotype controls. As depicted in Figure   1A and B, DARA, but not IPH2102, induced ADCC of MM cells in a dose-dependent manner. Interestingly, however, DARA-dependent ADCC was significantly augmented in the presence of IPH2102 (p<0.05), with a somewhat larger effect in the cell line RPMI8226
which is relatively resistant to DARA. These results suggested that blockade of KIR receptors can improve NK cell-mediated lysis by DARA.
To confirm these results in a more physiological setting, we employed our previously induced little or no lysis alone, even at a concentration of 10 µg/mL, which has been shown to saturate all KIR receptors. 14,15 However, 10 µg/mL of IPH2102 combined with DARA (>3 µg/mL), significantly enhanced DARA-mediated killing (p<0.05, Figure 1C) . Hence, in an extended analysis, in which we assessed BM-MNC from 21 patients, we tested both antibodies only at a saturating concentration of 10 µg/mL ( Figure 1D ). Again, IPH2102 alone was not able to induce MM cell lysis, but it significantly improved the DARA-dependent ADCC in these primary patient samples. A mixed model analysis indicated the synergistic action of DARA and IPH2102 to generate an average of 10% extra tumor cell lysis as the observed amount of tumor cell lysis significantly exceeded the expected levels, which were calculated with the assumption that the combinatorial effect was achieved only by additive effects ( Figure 1D ).
Impact of FcγR polymorphisms on the DARA-IPH2102 combination effect
Although the MM cell lysis was significantly increased by DARA-IPH2102 combination, the As mentioned, in our experiments IPH2102 alone induced little or no MM cell lysis ( Figure   1-3) . This is apparently inconsistent with previous reports, in which IPH2101 was found to induce NK cell cytotoxicity against lymphoma, acute myeloid leukemia (AML) cells and MM cells. 14, 27 While this latter study used IPH2101 at a higher (30 µg/mL) concentration than we did (10 µg/mL), this is probably not the reason for the observed apparent discrepancy, since earlier tests have demonstrated that KIRs are fully saturated above 10 µg/mL IPH2102. 14 On the other hand, it needs to be noted that the study in the AML setting was performed using purified and IL-2 activated NK-cells from HLA-C-matched healthy donors, which were furthermore used at higher NK: tumor ratios (10:1) to induce visible and significant tumor cell lysis above background levels. By contrast, we executed our experiments mainly in patientderived BM-MNC, thus without isolating the patient's own MM cells or NK cells from their natural environment. Consequently, in these experiments we readily achieve a median NK cell: MM cell ratio of 1:1 (data not shown), which generally does not induce significant MM cell lysis without addition of ADCC-inducing antibodies, like DARA. Another apparent discrepancy, which might be related to the differences in the experimental approach, is the absence of IPH2102-mediated MM cell lysis when combined with LEN in our setting, while previously IPH-LEN combinations were shown to improve MM cell lysis in both AML and MM settings. 13 In addition to the aforementioned experimental differences, our approach applied a lower dose of LEN (3 µM vs. 10 µM in other studies) since in a clinical setting it may be difficult to obtain LEN plasma levels above 3 µM without inducing adverse toxicities. 28 Our results, combining DARA with IPH2102, are fully compatible with the recent findings that anti-KIR antibodies augment the efficacy of ADCC-inducing antibodies like rituximab. 27 Accordingly, our results advocate that the best strategy to exploit the beneficial effects of IPH2102 may be in combination with ADCC-inducing antibodies. Furthermore, as we also show here, the ADCC-enhancing effects of IPH2102 with DARA can be further Genomic DNA available from PBMC from 16 patients tested in Figure 1D were typed for (A)
FcγRIIa 131 H/R and (B) FcγRIIIa 158 V/F polymorphisms on effector cells. The data obtained in figure 1D were then grouped according to the respective polymorphisms. Every circle represents an individual patient sample. The black bars indicate the group median value.
The observed (obs) lysis levels of MM cells with DARA-IPH2102 were compared to the expected lysis levels (exp), which were calculated with the assumption that the combinatorial effect is achieved by additive effects as indicated in methods. P-values were calculated by a paired t-test; ns means non significant, * p<0.05, ** p<0.01. were used at 0.01 µg/mL, 10 µg/mL and 3 µM, respectively. P-values are calculated using a paired student t test; ns means non significant, * p<0.05. Data shown represent mean ± SEM of 4 experiments (C) BM-MNC of 10 MM patients were incubated with DARA (10 µg/mL), LEN (3 µM), IPH2102 (10 µg/mL), combination treatments or control antibodies for 48h. The observed (obs) lysis levels of MM cells with DARA-IPH2102-LEN were compared to the expected lysis levels (exp), which were calculated with the assumption that the combinatorial effect is achieved by additive effects as indicated in methods. The black bars indicate the group mean value ± SEM. P-values are calculated using a paired student t test; ns means non significant, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
